Amneal Pharmaceuticals 

$16.16
72
-$0.08-0.49% Today

Statistics

Day High
16.35
Day Low
16.01
52W High
16.61
52W Low
7.67
Volume
9,478,094
Avg. Volume
-
Mkt Cap
5.08B
P/E Ratio
43.89
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
0.12
0.17
0.22
0.27
Expected EPS
0.22473
Actual EPS
N/A

Financials

2.39%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
6.04BRevenue
144.11MNet Income

Analyst Ratings

17.33Average Price Target
The highest estimate is 19.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AMRX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
Show more...
CEO
Mr. Chirag K. Patel
Employees
8300
Country
United States
ISIN
US03168L1052

Listings

0 Comments

Share your thoughts

FAQ

What is Amneal Pharmaceuticals stock price today?
The current price of AMRX is $16.16 USD — it has decreased by -0.49% in the past 24 hours. Watch Amneal Pharmaceuticals stock price performance more closely on the chart.
What is Amneal Pharmaceuticals stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Amneal Pharmaceuticals stocks are traded under the ticker AMRX.
Is Amneal Pharmaceuticals stock price growing?
AMRX stock has risen by +10.01% compared to the previous week, the month change is a +35.46% rise, over the last year Amneal Pharmaceuticals has showed a +99.26% increase.
What is Amneal Pharmaceuticals market cap?
Today Amneal Pharmaceuticals has the market capitalization of 5.08B
When is the next Amneal Pharmaceuticals earnings date?
Amneal Pharmaceuticals is going to release the next earnings report on August 12, 2026.
What were Amneal Pharmaceuticals earnings last quarter?
AMRX earnings for the last quarter are 0.27 USD per share, whereas the estimation was 0.17 USD resulting in a +59.64% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Amneal Pharmaceuticals revenue for the last year?
Amneal Pharmaceuticals revenue for the last year amounts to 6.04B USD.
What is Amneal Pharmaceuticals net income for the last year?
AMRX net income for the last year is 144.11M USD.
How many employees does Amneal Pharmaceuticals have?
As of June 16, 2026, the company has 8,300 employees.
In which sector is Amneal Pharmaceuticals located?
Amneal Pharmaceuticals operates in the Health & Wellness sector.
When did Amneal Pharmaceuticals complete a stock split?
The last stock split for Amneal Pharmaceuticals was on August 26, 2013 with a ratio of 1:25.
Where is Amneal Pharmaceuticals headquartered?
Amneal Pharmaceuticals is headquartered in Bridgewater, United States.